SCHEMBL29629922

SCHEMBL29629922

COc1ncccc1COc1ccc2oc(C)c(C(=O)NC3CNCC3(F)F)c2c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC26A4 O43511 4/20 0.45
MAPT P10636 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
LMNA P02545 3/20 0.43
TSHR P16473 2/20 0.43
SSTR4 P31391 1/20 0.42
GAA P10253 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
POLB P06746 2/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ROCK1 Q13464 1/20 0.40
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24484478 1.00 SLC26A4 (0.45) SLC26A4MAPTMEN1KMT2ALMNA
SCHEMBL24484911 0.93 SSTR4 (0.43) SLC26A4MAPTMEN1KMT2ALMNA
SCHEMBL29629813 0.93 SSTR4 (0.43) SLC26A4MAPTMEN1KMT2ALMNA
SCHEMBL29629865 0.92 SLC26A4 (0.47) SLC26A4MAPTMEN1KMT2ALMNA
SCHEMBL24485710 0.92 SLC26A4 (0.47) SLC26A4MAPTMEN1KMT2ALMNA
SCHEMBL24485071 0.89 SLC26A4 (0.44) SLC26A4MAPTMEN1KMT2ALMNA
SCHEMBL29630177 0.89 SLC26A4 (0.45) SLC26A4MAPTMEN1KMT2ALMNA
SCHEMBL24484484 0.89 SLC26A4 (0.45) SLC26A4MAPTMEN1KMT2ALMNA
SCHEMBL24484358 0.86 SSTR4 (0.43) SLC26A4MAPTMEN1KMT2ALMNA
SCHEMBL24470791 0.86 CASP3 (0.58) SLC26A4MAPTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070896-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2026-03-12 US claimed
US-12404266-B2 Heterocycle derivatives for treating TRPM3 mediated disorders KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-09-02 US claimed
EP-4251616-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven (BE) 2023-10-04 EP claimed
WO-2022112352-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO claimed
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-01-28 US disclosed
US-20240336602-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2024-10-10 US disclosed
WO-2022112352-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders TRPM4, TRPM6, TRPM2 SLC26A4 628/4885MAPT 2911/4885MEN1 1036/4885
US-12404266-B2 Heterocycle derivatives for treating TRPM3 mediated disorders TRPM4, TRPM6, TRPM2 SLC26A4 628/4885MAPT 2911/4885MEN1 1036/4885
US-20260070896-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM6, TRPV3, TRPM2 SLC26A4 482/4885MAPT 3196/4885MEN1 3849/4885
US-20240336602-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM4, TRPM6, TRPM2 SLC26A4 628/4885MAPT 2911/4885MEN1 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.